Capricor (CAPR): שווי כולל של נכסי החברה

Capricor Therapeutics (CAPR) relies on its own biopharmaceutical cell therapy ecosystem, creating a closed-loop cycle from the CAP-1002 platform to the clinics. Development efficiency is supported by partnerships with external research centers while keeping core technologies in-house. This chart illustrates the share price history relative to total assets, which have reached 251.15. However, global progress is being hindered by geopolitical conflicts that block cross-border testing and the logistics of biomaterials.

Total assets define the aggregate resource base of the company, combining equity and liabilities. Analyzing the total asset value on GURU.Markets allows for tracking financial stability dynamics through a reverse calculation of the ROA metric. This mechanism objectively records the value of assets, eliminating subjective assessments. For Capricor Therapeutics (CAPR), this indicator is critical, as it reflects the risk of balance sheet degradation amid costly clinical trials and the threat of equity dilution.